Yüklüyor......
Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis
Cabozantinib inhibits tyrosine kinase activity at the MET, AXL, and VEGF receptors and is approved for front-line therapy in metastatic clear cell renal cell carcinoma. Little off-protocol data exist on tolerability and response. The objective of this retrospective study was to assess off-protocol t...
Kaydedildi:
| Yayımlandı: | J Adv Pract Oncol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Harborside Press LLC
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7520741/ https://ncbi.nlm.nih.gov/pubmed/33343982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.4.2 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|